Published in Clin Biochem Rev on February 01, 2009
Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension (2015) 0.92
Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem (2012) 0.86
Catecholamines, steroids and immune alterations in ischemic stroke and other acute diseases. Aging Dis (2014) 0.78
The role of urinary fractionated metanephrines in the diagnosis of phaeochromocytoma. Indian J Med Res (2013) 0.78
Evaluation and validation of a method for determining platelet catecholamine in patients with obstructive sleep apnea and arterial hypertension. PLoS One (2014) 0.75
Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism. Clin Biochem Rev (2013) 0.75
Malignant catatonia mimicking pheochromocytoma. Case Rep Endocrinol (2013) 0.75
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
British Hypertension Society guidelines for hypertension management 1999: summary. BMJ (1999) 8.80
Phaeochromocytoma. Lancet (2005) 8.73
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. J Biol Chem (1964) 5.40
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab (2003) 3.25
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc (1981) 2.88
Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer (1997) 2.86
The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev (2004) 2.73
Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest (1980) 2.57
Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev (2004) 2.42
Incidentally discovered adrenal masses. Endocr Rev (1995) 2.40
Tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem (1999) 2.37
Clinical experience over 48 years with pheochromocytoma. Ann Surg (1999) 2.32
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res (2003) 2.29
Pheochromocytomas: can malignant potential be predicted? Urology (1999) 2.23
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med (1984) 2.09
von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92
Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem (2007) 1.74
Adrenal incidentaloma--experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med (2002) 1.74
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70
Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab (2003) 1.68
Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res (2004) 1.68
Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med (1995) 1.64
An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci (2006) 1.61
Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab (2007) 1.60
Plasma adrenaline, noradrenaline and dopamine in man and different animal species. J Physiol (1978) 1.60
Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol (1997) 1.53
Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab (2007) 1.51
Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med (1979) 1.49
An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol (2007) 1.47
Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem (1993) 1.47
The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens (1994) 1.46
The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol (2003) 1.41
Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) (2006) 1.41
Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand (1986) 1.39
Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol (1999) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab (1998) 1.34
Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) (1997) 1.24
Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med (2007) 1.24
Renal tubular drug transporters. Nephron Physiol (2006) 1.20
Measurement of catecholamines and their metabolites. Ann Clin Biochem (2004) 1.19
Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med (2000) 1.16
Pheochromocytoma. J Clin Hypertens (Greenwich) (2002) 1.15
Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol (2006) 1.09
Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine. BMJ (2001) 1.08
Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci (2006) 1.07
Simple and fast solvent extraction system for selective and quantitative isolation of adrenaline, noradrenaline and dopamine from plasma and urine. J Chromatogr (1982) 1.07
Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord (2001) 1.07
Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab (1995) 1.03
The binding of catecholamines to human serum proteins. Biochem Pharmacol (1975) 1.02
Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab (1999) 1.02
The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab (2004) 1.00
The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) (2007) 0.98
Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur J Endocrinol (2006) 0.98
The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med (1992) 0.98
The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) (2006) 0.97
Adrenal incidentalomas -- a continuing management dilemma. Endocr Relat Cancer (2005) 0.96
A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord (2004) 0.96
Epinephrine and norepinephrine responses in continuously collected human plasma to a series of stressors. Psychosom Med (1983) 0.96
New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann N Y Acad Sci (2002) 0.94
Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients. Ann N Y Acad Sci (2006) 0.94
Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem (2007) 0.93
Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem (2004) 0.93
A decade of HPLC-MS/MS in the routine clinical laboratory--goals for further developments. Clin Biochem (2008) 0.89
Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem (2002) 0.89
Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. Clin Chem (2006) 0.88
Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chromatography-tandem mass spectrometry. Clin Chem (2008) 0.88
A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer (2001) 0.88
Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin Chem (1994) 0.87
Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Ann N Y Acad Sci (2006) 0.87
Prediction of human pharmacokinetics - renal metabolic and excretion clearance. J Pharm Pharmacol (2007) 0.86
High-throughput, automated, and accurate biochemical screening for pheochromocytoma: are we there yet? Clin Chem (2007) 0.84
Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J Clin Oncol (2005) 0.84
Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging (2006) 0.84
Urinary catecholamine assay by HPLC: in vitro interference by some drugs. Ann Clin Biochem (1988) 0.83
Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma. Clin Chem (1991) 0.83
Renal handling of norepinephrine and epinephrine in the pig. Pflugers Arch (1985) 0.83
A simple, optimised and rapid assay for urinary free catecholamines by HPLC with electrochemical detection. Ann Clin Biochem (1985) 0.82
Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy. Clin Endocrinol (Oxf) (2007) 0.82
Free or total metanephrines for diagnosis of pheochromocytoma: what is the difference? Clin Chem (2001) 0.82
Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas. Endocr Pathol (2006) 0.81
Simultaneous determination of catecholamines and metanephrines in urine by HPLC with fluorometric detection. Clin Chim Acta (1984) 0.81
Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res (2008) 0.80
Analysis of catecholamines in urine by positive-ion electrospray tandem mass spectrometry. Clin Chem (2002) 0.80
Stability of urinary fractionated metanephrines and catecholamines during collection, shipment, and storage of samples. Clin Chem (2006) 0.80
Evaluation of specific high-performance liquid-chromatographic determinations of urinary metanephrine and normetanephrine by comparison with isotope dilution mass spectrometry. Ann Clin Biochem (2001) 0.79
47 years of phaeochromocytomas. Ir Med J (2001) 0.79
Plasma and urinary catecholamines as related to renal function in man. Kidney Int (1987) 0.79
Reboxetine treatment and pseudopheochromocytoma. QJM (2006) 0.78
Urinary normetanephrine and metanephrine measured by radioimmunoassay for the diagnosis of pheochromocytoma: utility of 24-hour and random 1-hour urine determinations. J Clin Endocrinol Metab (1988) 0.78
Preparation of urine samples for liquid-chromatographic determination of catecholamines: bonded-phase phenylboronic acid, cation-exchange resin, and alumina adsorbents compared. Clin Chem (1985) 0.78
Binding and clearance of radioactive adrenaline and noradrenaline in sheep blood. Vet Res Commun (2006) 0.78
Another cause of 'pseudophaeochromocytoma'--quetiapine associated with a false positive normetanephrine result. Clin Endocrinol (Oxf) (2007) 0.78
Clinical pharmacokinetics of metformin. Clin Pharmacokinet (2011) 2.59
The half-lives of plasma free metanephrines. Clin Endocrinol (Oxf) (2012) 1.42
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust (2012) 1.36
Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem (2009) 1.17
Detecting undiagnosed diabetes using glycated haemoglobin: an automated screening test in hospitalised patients. Med J Aust (2011) 0.94
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol (2011) 0.91
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol (2014) 0.89
Extreme diabetic lipaemia associated with a novel lipoprotein lipase gene mutation. Clin Chim Acta (2009) 0.85
BICEPP: an example-based statistical text mining method for predicting the binary characteristics of drugs. BMC Bioinformatics (2011) 0.82
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
A dose of paracetamol for the levothyroxine absorption test. Clin Endocrinol (Oxf) (2013) 0.80
Quantification of infant exposure to celecoxib through breast milk. Br J Clin Pharmacol (2006) 0.80
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling. Pharmacogenet Genomics (2016) 0.80
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol (2014) 0.79
An educational intervention to improve vancomycin prescribing and monitoring. Int J Antimicrob Agents (2013) 0.78
Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol (2013) 0.77
Mass or molar? Recommendations for reporting concentrations of therapeutic drugs. Med J Aust (2013) 0.76
Doctors and the pharmaceutical industry: time for a national policy? Med J Aust (2009) 0.75
Prediction of milk/plasma concentration ratio of drugs. Ann Pharmacother (2004) 0.75
Learning more from the dabigatran concentrations in the RE-LY study. J Am Coll Cardiol (2014) 0.75
What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century? Med J Aust (2009) 0.75
Free and total plasma cortisol measured by immunoassay and mass spectrometry following ACTH₁₋₂₄ stimulation in the assessment of pituitary patients. J Clin Endocrinol Metab (2013) 0.75